Press release – 2011
- November 9, 2011
Alethia Biotherapeutics announces promising in vivo results for its EMT inhibitor AB-16B5 and issuance of a patent for the role of secreted clusterin in EMT
- August 8, 2011
Alethia Biotherapeutics announces issuance of its second therapeutic target patent stemming from its proprietary target discovery platform
Alethia Press Release 110808 EN - June 3, 2011
Alethia Biotherapeutics announces partnership with Goodwin Biotechnologies for manufacturing of its monoclonal antibody, AB-16B5, an inhibitor of EMT for the treatment of cancer
GBI-Alethia PR 05-31-11 - May 26, 2011
Alethia Biotherapeutics announces issuance of its first therapeutic target patent emanating from its proprietary target discovery platform
Alethia Press Release 110526 EN - February 10, 2011
Alethia Biotherapeutics announces the nomination of Mr. Christopher J. Morl to the Board of Directors
Alethia press release 110210